S-OA-F
Oral Abstracts - Session F - Supportive Care
BMT Tandem "Scientific" Meeting
Texas C (Gaylord Texan)
Chairs:
Navneet S. Majhail, MD, MS
and
Nandita Khera, MD
Disclosures:
N. S. Majhail,
Nothing To Disclose
N. Khera,
Nothing To Disclose
Voriconazole Vs. Itraconazole for Antifungal Prophylaxis in Patients with GVHD: A Randomized Trial
Yoshiki Hayashi, National Cancer Center Hospital;
Yoshinobu Kanda, Saitama Medical Center, Jichi Medical University;
Hirohisa Nakamae, Osaka City University;
Heiwa Kanamori, Kanagawa Cancer Center;
Kazuteru Ohashi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital;
Michihiro Hidaka, MD, National Hospital Organization Kumamoto Medical Center;
Shingo Yano, Jikei University School of Medicine;
Kazuo Hatanaka, Wakayama Medical University;
Akio Kohno, JA Aichi Konan Kosei Hospital;
Yukiyoshi Moriuchi, Sasebo City General Hospital;
Hiroatsu Ago, Shimane Prefectural Central Hospital;
Takuya Yamashita, National Cancer Center Hospital;
Tohru Takata, Fukuoka University Hospital;
Minoru Yoshida, Teikyo University School of Medicine;
Masayuki Hino, Osaka City University;
Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine;
Takahiro Fukuda, MD, National Cancer Center Hospital
Comparison of Infection Rates Among Acute Leukemia Patients in Remission Receiving Alternative Donor Hematopoietic Cell Transplantation
Karen K. Ballen, MD, Massachusetts General Hospital;
Min Chen, MS, Medical College of Wisconsin;
Kwang Woo Ahn, PhD, Medical College of Wisconsin;
Michael J. Boeckh, MD, PhD, Fred Hutchinson Cancer Research Center;
Jeffery J. Auletta, MD, Nationwide Children's Hospital;
Paul Szabolcs, MD, Children's Hospital of Pittsburgh of UPMC;
Marcie Riches, MD, MS, H. Lee Moffitt Cancer Center
Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison Among Alternative Graft Sources
Karen K. Ballen, MD, Massachusetts General Hospital;
Navneet S. Majhail, MD, MS, Cleveland Clinic Foundation;
Ruta Brazauskas, PhD, Medical College of Wisconsin;
Zhiwei Wang, MS, The Medical College of Wisconsin;
Mahmoud D. Aljurf, MD, MPH, King Faisal Specialist Hospital and Research Centre;
Christopher Dandoy, MD, Cincinnati Children's Hospital Medical Center;
Haydar A. Frangoul, MD, Vanderbilt University Medical Center;
Cesar O. Freytes, MD, South Texas Veterans Health Care System and University of Texas Health Science Center San Antonio;
Hillard M. Lazarus, MD, University Hospitals Case Medical Center;
Charles F. LeMaistre, MD, Sarah Cannon;
Susan K. Parsons, MD, MRP, Tufts Medical Center;
Franklin O. Smith, MD, University of Cincinnati Medical Center;
Amir Steinberg, MD, Mount Sinai Medical Center;
David Szwajcer, MD, CancerCare Manitoba, University of Manitoba;
Celalettin Ustun, MD, University of Minnesota Medical Center;
William A. Wood, MD, MPH, University of North Carolina Hospitals;
Steven Joffe, MD, MPH, University of Pennsylvania, Perelman School of Medicine
Twice-Weekly Brincidofovir (CMX001) Shows Promising Antiviral Activity in Immunocompromised Transplant Recipients with Asymptomatic Adenovirus Viremia
Michael Grimley, MD, Cincinnati Children's Hospital Medical Center;
Vinod K. Prasad, MD, Duke University Medical Center;
Joanne Kurtzberg, MD, Duke University Medical Center;
Roy F Chemaly, MD, MPH, FIDSA, FACP, The University of Texas MD Anderson Cancer Center;
Thomas M Brundage, Chimerix, Inc.;
Chad Wilson, Chimerix, Inc.;
Herve Mommeja-Marin, MD, Chimerix, Inc.
Brincidofovir (CMX001) Is Well Tolerated in Highly Immunocompromised Pediatric Patients
Vinod K. Prasad, MD, Duke University Medical Center;
Michael Grimley, MD, Cincinnati Children's Hospital Medical Center;
Genovefa Papanicolaou, MD, Memorial Sloan-Kettering Cancer Center;
Lolie C Yu, MD, Children's Hospital;
Diana F Florescu, MD, University of Nebraska Medical Center;
Thomas M Brundage, Chimerix, Inc.;
Herve Mommeja-Marin, MD, Chimerix, Inc.;
Joanne Kurtzberg, MD, Duke University Medical Center
Robust Vaccine Responses in Double-Unit Cord Blood Transplantation (CBT) Recipients Despite Lack of Transfer of Memory T and B Cells
Leyla Shune, MD, Memorial Sloan-Kettering Cancer Center;
Duncan Purtill, MBBS, FRACP, FRCPA, Memorial Sloan-Kettering Cancer Center;
Marissa Lubin, BA, Memorial Sloan-Kettering Cancer Center;
Emily Lauer, BS, Memorial Sloan-Kettering Cancer Center;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Esperanza Papadopoulos, MD, Memorial Sloan-Kettering Cancer Center;
Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center;
Doris M. Ponce, MD, Memorial Sloan-Kettering Cancer Center;
Nancy Kernan, MD, Memorial Sloan-Kettering Cancer Center;
Andromachi Scaradavou, MD, New York Blood Center;
Juliet Barker, MBBS (Hons) FRACP, Memorial Sloan-Kettering Cancer Center
